Pharmaceutical

Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers’ Sensory Perceptions

VANCOUVER, BC / ACCESSWIRE / December 11, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing…

1 year ago

IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11,…

1 year ago

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

   Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory…

1 year ago

Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited

KELOWNA, BC / ACCESSWIRE / December 11, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology…

1 year ago

Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care

Agreement Expands Partnership Between Cosmo Pharmaceuticals and Medtronic, Set to Transform Endoscopy with Cutting-Edge AI Technology Ad hoc announcement pursuant…

1 year ago

Poolbeg Pharma PLC Announces POLB 001 Data Presented at ASH

POLB 001 - targeting Cytokine Release Syndrome (CRS) associated with cancer immunotherapiesLONDON, UK / ACCESSWIRE / December 11, 2023 /…

1 year ago

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo – – Improvements Observed in Annualized…

1 year ago

Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts

BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetesAt…

1 year ago